Permax® Defective Drug – Rhode Island and Massachusetts Lawyers
The U.S. Food and Drug Administration (FDA) announced that manufacturers of Pergolide drug products, which are used to treat Parkinson’s disease, will voluntarily remove these drugs from the market because of the risk of serious damage to patients’ heart valves.
Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals, and two generic versions of Pergolide manufactured by Par and Teva.
On March 29, 2006, the FDA withdrew Permax (pergolide) from the market because it increases the risk of valvular heart disease.
Our lawyers will provide you with a free case evaluation. – Contact Brian Cunha & Associates.